N/A N=174 Adapting Tools to Implement Stroke Risk Management to Veterans
Ischemic Stroke · Transient Ischemic Attack
Primary: Stroke Specific Health Related Quality of Life — 3.80; 3.94; 2.98; 3.04 units on a scale — p=0.69
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=61 Study of Pharmacology of 17-OHPC in Pregnancy
Pregnancy
Primary: Change in the Area Under the Concentration vs. Time Curve in the Second and Third Trimesters of Pregnancy. — 115; 136 ng/ML/day
Phase 4 N=50 Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan
Allergic Conjunctivitis
Primary: Mean Ocular Itching at 7 Minutes Post-CAC, Day 1 — 0.23; 0.37 units on a scale
Phase 3 N=846 Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes
Metabolism and Nutrition Disorder · Obesity
Primary: Change (%) From Baseline in Body Weight (Fasting) — -5.9; -4.6; -2.0 percent change — p=<0.0001
N/A N=66 Wearable Pulsed Electromagnetic Fields Device in Knee Osteoarthritis: Double Blinded, Randomized Clinical Trial
Knee Osteoarthritis
Primary: Change From Baseline in Pain Perception Measured on Visual Analog Score (VAS) at Week 4 — 67; 63.6; 50; 61 units on a scale — p=<0.0001
Phase 2 N=10 Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Biochemical Response Rate — 383; 550; 43; 53 U/mL
N/A N=464 Tailored Communication to Reduce Cardiovascular Risk
Hypercholesterolemia · Coronary Artery Disease · Dyslipidemia
Primary: Comparative Outcomes: Intervention Group LDL Reduction Compared to Control Group LDL Reduction — 11.0; 11.1 % of patients with major LDL reduction — p=0.99
Phase 3 N=359 Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Metabolism and Nutrition Disorder · Obesity · Obstructive Sleep Apnoea
Primary: Change From Baseline in Apnoea-hypopnoea Index (AHI) — -12.22; -6.08 events/hour — p=0.015
N/A N=51 The Effect of Exercise on Individuals With Parkinson's Disease
Parkinson's Disease
Primary: Off Medication UPDRS Part III, Motor Subscale Score — 34.7; 34.5; 29.3; 28.0 units on a scale
Phase 2 N=126 Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma
Esophageal Cancer · Gastroesophageal Cancer
Primary: Pathologic Complete Response Rate — 13; 26 percentage of participants
Phase 3 N=547 A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures
Epilepsy · Partial Onset Seizures
Primary: Change in Partial-Onset Seizure Frequency Per 28 Days From Baseline to the Maintenance Period — -1.22; -3.33; -4.50 Seizures per 28 days — p=<0.001
Phase 2 N=63 A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
Tumors
Primary: Progression Free Survival (PFS) in the Intent-to-Treat Population — 9.3; 8.6 months
Phase 2 N=264 A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
Venous Thromboembolism · Thromboembolism · Thrombosis
Primary: Percentage of Subjects With Venous Thromboembolism Events — 3.8; 2.8; 4.1 percent of participants with VTE event
Phase 2 N=30 Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Response Rate to the Combination of Gemcitabine and Docetaxel in Patients With Platinum Sensitive and Resistant Epithelial Ovarian or Peritoneal Cancer. — 62 percentage…
Phase 4 N=45 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response
Philadelphia Chromosome Positive · Chronic Myelogenous Leukemia in Chronic Phase
Primary: MMR Rate at 12 Mos. of Nilotinib Treatment on Study in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who…